Sara Quenet
Overview
Explore the profile of Sara Quenet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
315
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hughes T, Saglio G, Geissler J, Kim D, Lomaia E, Mayer J, et al.
J Hematol Oncol
. 2024 Dec;
17(1):125.
PMID: 39696526
Background: Up to 65% of patients with chronic myeloid leukemia (CML) who are treated with imatinib do not achieve sustained deep molecular response, which is required to attempt treatment-free remission....
2.
Hochhaus A, Rea D, Boquimpani C, Minami Y, Cortes J, Hughes T, et al.
Leukemia
. 2023 Jan;
37(3):617-626.
PMID: 36717654
Asciminib, the first BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP), is approved worldwide for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase...
3.
Rea D, Mauro M, Boquimpani C, Minami Y, Lomaia E, Voloshin S, et al.
Blood
. 2021 Aug;
138(21):2031-2041.
PMID: 34407542
Patients with chronic myeloid leukemia in chronic phase (CML-CP) resistant/intolerant to ≥2 tyrosine kinase inhibitors (TKIs) are at high risk of experiencing poor outcomes because of disease biology and inadequate...
4.
Hijiya N, Maschan A, Rizzari C, Shimada H, Dufour C, Goto H, et al.
Blood
. 2019 Sep;
134(23):2036-2045.
PMID: 31511239
Chronic myeloid leukemia (CML) is rare in children and accounts for ≤15% of all myeloid leukemia cases. When we initiated this study with nilotinib, imatinib was the only tyrosine kinase...
5.
Boutet C, Rouffiange-Leclair L, Garnier P, Quenet S, Delsart D, Varvat J, et al.
Eur J Radiol
. 2014 Mar;
83(5):824-8.
PMID: 24582173
Purpose: To compare magnetic resonance imaging (MRI) brain feature in cryptogenic stroke patients with patent foramen ovale (PFO), cryptogenic stroke patients without PFO and patients with cardioembolic stroke. Materials And...
6.
Gouin-Thibault I, Flaujac C, Delavenne X, Quenet S, Horellou M, Laporte S, et al.
Thromb Haemost
. 2013 Nov;
111(2):240-8.
PMID: 24172843
While laboratory monitoring is not required in patients treated with apixaban, a direct factor-Xa inhibitor, assessment of its concentration is useful in some critical situations. However, few data are available...
7.
Bertoletti L, Quenet S, Laporte S, Sahuquillo J, Conget F, Pedrajas J, et al.
Respir Res
. 2013 Jul;
14:75.
PMID: 23865769
Background: Patients with chronic obstructive pulmonary disease (COPD) have a modified clinical presentation of venous thromboembolism (VTE) but also a worse prognosis than non-COPD patients with VTE. As it may...
8.
Chauleur C, Quenet S, Varlet M, Seffert P, Laporte S, Decousus H, et al.
Thromb Res
. 2008 Feb;
122(4):478-84.
PMID: 18280547
Introduction: Management of pregnant women at increased risk of venous thromboembolism (VTE) remains complex in the absence of an easy-to-use tool allowing individualised, risk-adapted prophylaxis. Our objective was to assess...
9.
Decousus H, Moulin N, Quenet S, Bost V, Rivron-Guillot K, Laporte S, et al.
Thromb Res
. 2007 Nov;
120 Suppl 2:S51-61.
PMID: 18023713
Venous thrombosis is a common and severe complication in patients with cancer. We reviewed studies assessing whether a state of acquired or congenital thrombophilia influenced the risk of thrombosis in...
10.
Mismetti P, Rivron-Guillot K, Quenet S, Decousus H, Laporte S, Epinat M, et al.
Chest
. 2007 Jan;
131(1):223-9.
PMID: 17218580
Background: The immediate and long-term clinical events associated with the placement and removal of a retrievable filter (ALN filter; ALN Implants Chirurgicaux; Ghisonaccia, France) remain largely unknown. Methods: This was...